NCT07137390 2026-03-11
A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
Clinical Trials
532 trialsNCT06608940 2026-02-19
BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma
Case Comprehensive Cancer Center
Phase 1/2 Withdrawn
NCT06217094 2026-02-18
Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment
University of Florida
Phase 1 Withdrawn
NCT05312372 2026-02-17
S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC
Servier
Phase 1/2 Withdrawn
NCT05360745 2026-02-11
FOODPANC
Fundacion para la Excelencia y la Calidad de la Oncologia
Phase NA Withdrawn
NCT05512260 2026-02-11
BESTa
Karolinska Institutet
Phase NA Withdrawn
NCT06501989 2026-02-11
Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer
Inova Health Care Services
Phase 2 Withdrawn
NCT07323576 2026-02-09
INAVO-CRC
Hoffmann-La Roche
Phase 2 Withdrawn
NCT05175092 2026-02-06
Living Donor Liver Transplantation for CRC Liver Metastases
University of Wisconsin, Madison
Phase NA Withdrawn
NCT05044312 2026-01-23
Sleep Disturbances in Surgical Patients With GI Cancers: A Quantitative and Qualitative Analysis
M.D. Anderson Cancer Center
Phase NA Withdrawn
NCT07283848 2025-12-26
Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma
Massachusetts General Hospital
Phase 2 Withdrawn
NCT06626256 2025-12-24
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
City of Hope Medical Center
Phase 1 Withdrawn
NCT06994299 2025-11-18
PRISM
Weill Medical College of Cornell University
Phase 2 Withdrawn
NCT07026916 2025-11-17
A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer
Genfleet Therapeutics (Shanghai) Inc.
Phase 2 Withdrawn
NCT03546660 2025-10-22
Imaging of the Esophagus Using a SECM Capsule
Massachusetts General Hospital
Phase NA Withdrawn
NCT06557278 2025-10-21
COMUNITY
Mirror Biologics, Inc.
Phase 2 Withdrawn
NCT03879161 2025-10-16
A Percutaneous Ultrasound Device With Needle Guide for Vascular Access
Johns Hopkins University
Phase NA Withdrawn
NCT06730100 2025-10-06
CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT06410534 2025-09-11
A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT06690281 2025-09-11
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT04031872 2025-09-05
LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)
The Netherlands Cancer Institute
Phase 1/2 Withdrawn
NCT05737615 2025-09-04
PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers With Elevated CA19.9
Memorial Sloan Kettering Cancer Center
Phase 1 Withdrawn
NCT06084689 2025-09-02
EMPIRE
Institut Bergonié
Phase 2 Withdrawn
NCT06217016 2025-08-28
Effect of ICCAUT Strategy on Postoperative Urinary Retention After Radical Rectal Cancer Surgery (ICCAUT-2)
The First Hospital of Jilin University
Phase NA Withdrawn
NCT06420908 2025-08-26
Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)
Hebei Medical University Fourth Hospital
Phase NA Withdrawn
NCT00417001 2025-08-17
Reduction of Conscious Sedation Requirements by Olfactory Stimulation
United States Naval Medical Center, Portsmouth
Phase NA Withdrawn
NCT05678205 2025-07-30
A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors
Artiva Biotherapeutics, Inc.
Phase 1/2 Withdrawn
NCT05917990 2025-07-28
Dyadic Text-Messaging Micro-Intervention
Duke University
Phase NA Withdrawn
NCT05634525 2025-07-25
Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT04571710 2025-07-24
A Trial of SHR1258 in Patients With Biliary Tract Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Withdrawn
NCT06498518 2025-07-11
PRIMUS006
University of Glasgow
Phase 2 Withdrawn
NCT04906954 2025-07-03
DIGELECTROSTIM
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase NA Withdrawn
NCT06707896 2025-06-25
TCR1020-CD8 T Cells in KRAS-mutated Cancers
University of Pennsylvania
Phase 1 Withdrawn
NCT06361758 2025-05-23
Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC
Shanghai Zhongshan Hospital
Phase 2 Withdrawn
NCT06895577 2025-05-21
Neoadjuvant Chemoradiotherapy Plus Sintilimab for MSS, Locally Advanced Rectal Cancer-
Sun Yat-sen University
Phase 2 Withdrawn
NCT03879811 2025-05-15
Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Withdrawn
NCT03374852 2025-04-29
CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer
Thomas Jefferson University
Phase 2 Withdrawn
NCT02939807 2025-04-27
A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma
Medical University of South Carolina
Phase 2 Withdrawn
NCT05940844 2025-04-09
Study of OB-002 in Patients With Refractory Metastatic Cancer
Orion Biotechnology Polska Sp. z o.o.
Phase 1 Withdrawn
NCT04180761 2025-04-03
ProPeC
University Hospital Tuebingen
Phase 2 Withdrawn
NCT01369316 2025-03-27
CSIEMR
Western Sydney Local Health District
Phase NA Withdrawn
NCT01372696 2025-03-27
C-LST
Western Sydney Local Health District
Phase NA Withdrawn
NCT02004782 2025-03-27
BERST
Western Sydney Local Health District
Phase 4 Withdrawn
NCT03636607 2025-03-24
Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions of Primary Hepatocellular Carcinoma
Fifth Affiliated Hospital, Sun Yat-Sen University
Phase NA Withdrawn
NCT04976660 2025-03-18
TT-4 As a Single Agent in Subjects with Advanced Selected Solid Tumors
Portage Biotech
Phase 1/2 Withdrawn
NCT06144827 2025-03-18
HepQuant
Montefiore Medical Center
Phase NA Withdrawn
NCT05584540 2025-03-12
UNTIRE: Cancer-related Fatigue With Digital Treatment
Dana-Farber Cancer Institute
Phase NA Withdrawn
NCT03541486 2025-03-10
XACT-PANC-2
University of Iowa
Phase 2 Withdrawn
NCT03169777 2025-02-21
QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT04863430 2025-02-21
Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach
Peking University
Phase 2 Withdrawn